Viral Characteristic of HIV Infected Patients Naïf of Anti-Retroviral Therapy with CD4+ T Lymphocytes Rate Greater than 350 per Microliter of Blood in Lomé Togo

Abstract Full-Text HTML Download Download as PDF (Size:122KB) PP. 364-366
DOI: 10.4236/wja.2013.34047    2,205 Downloads   3,190 Views   Citations

ABSTRACT

Objective: To evaluate the virological status of ineligible HIV patients for anti-retroviral therapy based on the criterion of CD4+ T lymphocytes rate over than 350/μl of blood. Method: This is a prospective study which was conducted from November 2011 to July 2012 in the tropical and infectious disease department of CHU Sylvanus Olympio of Lomé. All HIV-1 infected patients whose CD4+ T lymphocytes rate was ≥350/μl of blood were retained. The count of CD4+ T lymphocytes was made by cytometer FACSCalibur? flow of BD biosciences and the determination of viral load was achieved by NASBA laboratory method of Biomérieux. Results: We have recruited 102 PLWHA aged between 19 and 58 years with a median of 35 years. Biologically, 102 patients had a T-CD4 rate between 355 and 432/μl of blood. The determination of viral load showed a very high viral replication more than 10,000 copies/ml among all patients and 28 (27.5%) patients had a viral load > 100,000 copies/ml of blood. Conclusion: Our results argue for a reconsideration of the criteria for starting antiretroviral therapy in Togo by including virological data if necessary in patients with T-CD4 rate below 500/μl of blood.

Cite this paper

I. Wateba, A. Patassi, A. Balaka and O. Tidjani, "Viral Characteristic of HIV Infected Patients Naïf of Anti-Retroviral Therapy with CD4+ T Lymphocytes Rate Greater than 350 per Microliter of Blood in Lomé Togo," World Journal of AIDS, Vol. 3 No. 4, 2013, pp. 364-366. doi: 10.4236/wja.2013.34047.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] PNLS-INFO No. 001/2007 PNLS-Togo, 2007, 1-5.
[2] PNLS, “Directives Pour une Prise en Charge Avec les Médicaments Antirétroviraux (ARV) au Togo,” 2004, pp 3-9.
[3] PNLS, “Guide National de la Prise en Charge Médiacle du VIH/SIDA: Affections Opportunistes et Traitement par les Antirétroviraux,” 2004, p. 104.
[4] OMS, “Recommendation Pour une Approche de Santé Publique: Améliorer L’accès aux Traitements Antirétroviraux dans les Pays à Ressources Limitées,” 2002, pp. 8-9.
[5] ONUSIDA, “Rapport sur l’épidémie Mondiale de SIDA,” ONUSIDA, Genève, 2006, pp. 3-4.
[6] R. D. Moore and J. C. Keruly, “CD4+ Cell Count 6 Years after Commencement of Highly Active Antiretroviral Therapy in Person with Sustained Virologic Suppression,” Clinical Infectious Diseases, Vol. 44, No. 3, 2007, pp. 441-446. http://dx.doi.org/10.1086/510746
[7] J. V. Baker, G. Peng, J. Rapkin, et al., “CD4+ Count and Risk of Non-AIDS Diseases Following Initial Treatment for HIV Infection,” AIDS, Vol. 22, No. 7, 2008, pp. 841-888.
http://dx.doi.org/10.1097/QAD.0b013e3282f7cb76
[8] S. Emery, J. A. Neuhaus, A. N. Phillips, et al., “Major Clinical Outcomes in Antiretroviral Therapy (ART)-Naive Participants and in Those Not Receiving ART at Baseline in the SMART Study,” Journal of Infectious Diseases, Vol. 197, No. 8, 2008, pp. 1133-1144.
http://dx.doi.org/10.1086/586713
[9] HIV-CAUSAL Collaboration, et al., “The Effect of Combined Antiretroviral Therapy on the Overall Mortality of HIV-Infected Individuals,” AIDS, Vol. 24, No. 1, 2010, pp. 123-137.
http://dx.doi.org/10.1097/QAD.0b013e3283324283
[10] M. Guiguet, F. Boue, J. Cadranel, J. M. Lang, E. Rosenthal and D. Costagliola, “Effect of Immunodeficiency, HIV Viral Load, and Antiretroviral Therapy on the Risk of Individual Malignancies (FHDH-ANRS CO4): A Prospective Cohort Study,” Lancet Oncology, Vol. 10, No. 12, 2009, pp. 1152-1159.
http://dx.doi.org/10.1016/S1470-2045(09)70282-7
[11] C. F. Kelley, C. M. Kitchen, P. W. Hunt, et al., “Incomplete Peripheral CD4+ Cell Count Restoration in HIV Infected Patients Receiving Long-Term Antiretroviral Treatment,” Clinical Infectious Diseases, Vol. 48, No. 6, 2009, pp. 787-794. http://dx.doi.org/10.1086/597093
[12] M. Egger, M. May, G. Chêne, et al., “Prognosis of HIV-1-Infected Patients Starting Highly Active Antiretroviral Therapy: A Collaborative Analysis of Prospective Studies,” Lancet, Vol. 360, No. 9327, 2002, pp. 119-129.
http://dx.doi.org/10.1016/S0140-6736(02)09411-4
[13] J. P. Phair, J. W. Mellors, R. Detels, J. B. Margolick and A. Munoz, “Virologic and Immunologic Values Allowing Safe Deferral of Antiretroviral Therapy,” AIDS, Vol. 16, No. 18, 2002, pp. 2455-2459.
http://dx.doi.org/10.1097/00002030-200212060-00011
[14] E. Wood, R. S. Hogg, B. Yip, et al., “Higher Baseline Levels of Plasma Human Immunodeficiency Virus Type 1 RNA Are Associated with Increased Mortality after Initiation of Triple-Drug Antiretroviral Therapy,” Journal of Infectious Diseases, Vol. 188, No. 10, 2003, pp. 1421-1425.
http://dx.doi.org/10.1086/379201
[15] Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, et al., “Response to Combination Antiretroviral Therapy: Variation by Age,” AIDS, Vol. 22, No. 12, 2008, pp. 1463-1473.
http://dx.doi.org/10.1097/QAD.0b013e3282f88d02
[16] A. H. Greenbaum, L. E. Wilson, J. C. Keruly, R. D. Moore and K. A. Gebo, “Effect of Age and HAART Regimen on Clinical Response in an Urban Cohort of HIV-Infected Individuals,” AIDS, Vol. 22, No. 17, 2008, pp. 2331-2339.
http://dx.doi.org/10.1097/QAD.0b013e32831883f9

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.